Last reviewed · How we verify
GSK Biologicals' influenza vaccine GSK2186877A
GSK Biologicals' influenza vaccine GSK2186877A is a Influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of influenza infection in adults.
GSK2186877A is an influenza vaccine that stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains.
GSK2186877A is an influenza vaccine that stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains. Used for Prevention of influenza infection in adults.
At a glance
| Generic name | GSK Biologicals' influenza vaccine GSK2186877A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As an influenza vaccine, GSK2186877A works by presenting viral antigens to the immune system, triggering both humoral (antibody-mediated) and cellular immune responses. This primes the body to recognize and rapidly respond to natural influenza infection, reducing disease severity and transmission. The specific formulation and adjuvant strategy of GSK2186877A is designed to enhance immunogenicity compared to standard seasonal influenza vaccines.
Approved indications
- Prevention of influenza infection in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children (PHASE1)
- Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly (PHASE3)
- Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older (PHASE3)
- Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly (PHASE3)
- Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older (PHASE3)
- Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' influenza vaccine GSK2186877A CI brief — competitive landscape report
- GSK Biologicals' influenza vaccine GSK2186877A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' influenza vaccine GSK2186877A
What is GSK Biologicals' influenza vaccine GSK2186877A?
How does GSK Biologicals' influenza vaccine GSK2186877A work?
What is GSK Biologicals' influenza vaccine GSK2186877A used for?
Who makes GSK Biologicals' influenza vaccine GSK2186877A?
What drug class is GSK Biologicals' influenza vaccine GSK2186877A in?
What development phase is GSK Biologicals' influenza vaccine GSK2186877A in?
What are the side effects of GSK Biologicals' influenza vaccine GSK2186877A?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of influenza infection in adults
- Compare: GSK Biologicals' influenza vaccine GSK2186877A vs similar drugs
- Pricing: GSK Biologicals' influenza vaccine GSK2186877A cost, discount & access